Status:
UNKNOWN
Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Chronic Kidney Diseases
Hyperkalemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
This study hypothesizes that the administration of Sodium zirconium cyclosilicate in CKD patients with hyperkalemia while avoiding dietary potassium restriction will normalize their serum potassium le...
Detailed Description
A diet rich in fruits and vegetables is associated with better outcomes in CKD patients. However, the presence of hyperkalemia can prevent patients from increasing plant-based foods in their diets. Wh...
Eligibility Criteria
Inclusion
- Men and women over the age of 18
- CKD stage 3-4 with an estimated GFR less or equal to 45 mL/min but greater than 15 mL/min
- Serum potassium level ≥5 mEq/L on two blood tests in the past 3 months but less than 6.5mEq/L
Exclusion
- On dialysis
- Have been on SZC in the past 3 months
- Reside in a nursing home
- Pregnant patients
- Patients with known cognitive disability
- History of bowel disease such as but not limited to short bowel syndrome, bowel obstruction, inflammatory bowel disease
Key Trial Info
Start Date :
March 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 15 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04727840
Start Date
March 15 2021
End Date
January 15 2022
Last Update
February 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115